6 results about "Beta blocker" patented technology

Transdermal delivery of beta blockers to treat Infantile Hemangiomas (IH) with reduced systemic circulation of the active drug and reduced or eliminated drug exposure to internal organs. In some embodiments, the beta blocker is esmolol. Pharmaceutical compositions according to the invention may be formulated lotions, creams, ointments, gels, foams, liquid dispersions, solutions, or aerosols.

A pharmaceutical composition comprising a diuretic and at least one additional active ingredient selected from the group consisting of ACE inhibitors, sartans, calcium channel blockers, alpha blockers, and beta blockers, wherein the diuretic is in a first pharmaceutical form that increases its dissolving rate. The invention also relates to the above composition for use in the treatment of a condition selected from heart failure, arterial hypertension, myocardial fibrosis, and cardiac hypertrophy.

Disclosed herein are methods of treating or preventing headaches (e.g., migraines) and / or photophobia in a subject comprising administering a pharmaceutical composition comprising one or more therapeutic agents selected from a triptan, a beta blocker, an alpha agonist, and a CORP antagonist.

In various aspects and embodiments, compositions and methods for identifying patients in need of improved cognition and / or treatment of neurodegenerative diseases in patients and treating such patients are provided. More specifically, in some embodiments, the present disclosure comprises administering a beta-AR agonist (such as a beta agent) and a peripherally acting beta blocker (PABRA) to a patient in need thereof.

Compositions and methods for treating or preventing a condition related to myocardial infarction and infarct expansion, extension, and / or dilation following a cardiovascular disorder incident (e.g., post-myocardial infarction) using an effective amount of RRx-001, or a pharmaceutically acceptable salt thereof, are described. In some embodiments, an agent (such as a statin, an angiotension-converting-enzyme (ACE) inhibitor, aspirin, oxygen, a nitric oxide donor, a drug-eluting stent, an anticoagulant or antiplatelet therapy, a phosphodiesterase-5 inhibitor, a calcium channel blocker, an angiotensin II receptor blocker (ARB), a beta blocker, an aldosterone antagonist, a loop diuretic, an epigenetic inhibitor, and / or a nitrite) is administered prior to, concurrently with, or subsequent administering the effective amount of RRx-001, or a pharmaceutically acceptable salt thereof. In some embodiments, the effective amount of RRx-001, or a pharmaceutically acceptable salt thereof, is administered as a composition comprising a blood product and / or the agent.

The present invention relates to a composition for treating neurodegenerative diseases comprising a beta blocker and a cholinesterase inhibitor and, more specifically, to a composition that relieves neuroinflammation, promotes nerve cell differentiation and shows antioxidant effects to exhibit synergistic effects on degenerative neurological diseases.